DE3418651A1 - Arzneimittel zur behandlung der essentiellen hypertonie und des myokardinfarkts - Google Patents
Arzneimittel zur behandlung der essentiellen hypertonie und des myokardinfarktsInfo
- Publication number
- DE3418651A1 DE3418651A1 DE19843418651 DE3418651A DE3418651A1 DE 3418651 A1 DE3418651 A1 DE 3418651A1 DE 19843418651 DE19843418651 DE 19843418651 DE 3418651 A DE3418651 A DE 3418651A DE 3418651 A1 DE3418651 A1 DE 3418651A1
- Authority
- DE
- Germany
- Prior art keywords
- day
- changes
- medicament according
- animals
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 208000007530 Essential hypertension Diseases 0.000 title claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 10
- 239000008024 pharmaceutical diluent Substances 0.000 claims abstract description 6
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 229910002012 Aerosil® Inorganic materials 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000644 isotonic solution Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 229940079593 drug Drugs 0.000 description 23
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 19
- 230000004872 arterial blood pressure Effects 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 206010028851 Necrosis Diseases 0.000 description 11
- 210000004413 cardiac myocyte Anatomy 0.000 description 11
- 206010014950 Eosinophilia Diseases 0.000 description 10
- 206010062575 Muscle contracture Diseases 0.000 description 10
- 208000006111 contracture Diseases 0.000 description 10
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 9
- 230000001077 hypotensive effect Effects 0.000 description 9
- 230000017074 necrotic cell death Effects 0.000 description 9
- 210000004351 coronary vessel Anatomy 0.000 description 8
- 230000037390 scarring Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 7
- 210000002808 connective tissue Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 210000002751 lymph Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 210000005240 left ventricle Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 208000012868 Overgrowth Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000207925 Leonurus Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000033687 granuloma formation Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- ATADHKWKHYVBTJ-UHFFFAOYSA-N hydron;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;chloride Chemical compound Cl.CNCC(O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 229940095990 inderal Drugs 0.000 description 2
- 230000000053 inderal effect Effects 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008023 pharmaceutical filler Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- -1 tranquillizers Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CEMAWMOMDPGJMB-CYBMUJFWSA-N (2r)-1-(propan-2-ylamino)-3-(2-prop-2-enoxyphenoxy)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-CYBMUJFWSA-N 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 244000299906 Cucumis sativus var. sativus Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229950009941 chloralose Drugs 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002497 edematous effect Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000192 parasympathetic ganglia Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU3593392 | 1983-05-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3418651A1 true DE3418651A1 (de) | 1984-11-22 |
| DE3418651C2 DE3418651C2 (enExample) | 1987-11-05 |
Family
ID=21064187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19843418651 Granted DE3418651A1 (de) | 1983-05-18 | 1984-05-18 | Arzneimittel zur behandlung der essentiellen hypertonie und des myokardinfarkts |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4568689A (enExample) |
| JP (1) | JPS59222416A (enExample) |
| CA (1) | CA1229553A (enExample) |
| DE (1) | DE3418651A1 (enExample) |
| FR (1) | FR2548899B1 (enExample) |
| GB (1) | GB2142533B (enExample) |
| IT (1) | IT1196109B (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2319278C2 (de) * | 1973-04-17 | 1986-02-20 | Bayer Ag, 5090 Leverkusen | Pharmazeutisches Mittel |
| US3974176A (en) * | 1973-08-16 | 1976-08-10 | Byk-Gulden Lomberg Chemische Fabrik Gmbh | Halogen pyrazoles derivatives, a method for producing these halogen pyrazole derivatives and medicaments containing them |
| LU71847A1 (enExample) * | 1975-02-14 | 1977-01-05 | ||
| SU747855A1 (ru) * | 1978-04-12 | 1980-07-15 | Ташкентский Ордена Трудового Красного Знамени Медицинский Институт | 3-Пиразолилметиловый эфир пропионовой кислоты, обладающий противовоспалительной активностью |
| GB2073740A (en) * | 1980-03-03 | 1981-10-21 | Wellcome Found | Pyrazolidinones |
-
1984
- 1984-05-07 CA CA000453725A patent/CA1229553A/en not_active Expired
- 1984-05-15 GB GB08412342A patent/GB2142533B/en not_active Expired
- 1984-05-16 IT IT20949/84A patent/IT1196109B/it active
- 1984-05-16 US US06/610,634 patent/US4568689A/en not_active Expired - Fee Related
- 1984-05-18 FR FR8407799A patent/FR2548899B1/fr not_active Expired
- 1984-05-18 JP JP59100328A patent/JPS59222416A/ja active Pending
- 1984-05-18 DE DE19843418651 patent/DE3418651A1/de active Granted
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT * |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3418651C2 (enExample) | 1987-11-05 |
| GB2142533B (en) | 1987-03-04 |
| IT1196109B (it) | 1988-11-10 |
| CA1229553A (en) | 1987-11-24 |
| GB8412342D0 (en) | 1984-06-20 |
| US4568689A (en) | 1986-02-04 |
| JPS59222416A (ja) | 1984-12-14 |
| IT8420949A0 (it) | 1984-05-16 |
| FR2548899B1 (fr) | 1989-01-06 |
| IT8420949A1 (it) | 1985-11-16 |
| FR2548899A1 (fr) | 1985-01-18 |
| GB2142533A (en) | 1985-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19542281C2 (de) | Verwendung von Epinastin für die Behandlung der Migräne | |
| DE2856393A1 (de) | Mittel zur behandlung des zentralnervensystems | |
| DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
| DE19922443A1 (de) | Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen | |
| DE69620186T2 (de) | Neue medizinische verwendung | |
| DE69624253T2 (de) | Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren | |
| DE3779842T2 (de) | Antiallergisches mittel. | |
| DE2750159C3 (de) | Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung | |
| DE3418651C2 (enExample) | ||
| CH641680A5 (de) | Verfahren zur herstellung injizierbarer insulinpraeparate. | |
| DE1915497A1 (de) | Arzneimittel mit hypolipidaemischer und hypocholesterinaemischer Wirksamkeit | |
| DE2333831C3 (de) | l-(2-Benzoyl-äthyl)-2-(4-a- cinnamylpiperazinomethyQ-benzimidazole, Verfahren zur ihrer Herstellung und ihre therapeutische Verwendung | |
| DE2528460A1 (de) | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans | |
| DE2421349A1 (de) | Pharmazeutisches praeparat zur behandlung von koronarerkrankungen | |
| DE1470012B2 (de) | Papaverinsalz der 7-theophyllin-n- propan-omega-sulfonsaeure | |
| DE2828200A1 (de) | Verwendung von tetramisole oder levamisole oder deren salzen bei der bekaempfung von scabies (kraetze) | |
| DE1617822A1 (de) | Neues Kombinationspraeparat | |
| DE2145359B2 (de) | 1-eckige klammer auf buten-(2)ylidenhydrazino eckige klammer zu phthalazinderivate | |
| DE2413803A1 (de) | Pharmazeutische zusammensetzungen aus gemischten salzen von sulfoglykopeptiden mit metallbasen und organischen basen | |
| DD283931A5 (de) | Verfahren zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von herzrhythmusstoerungen | |
| DE2118242C3 (de) | Decylester von Prostaglandin E tief 1 und E tief 2, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE3306128C2 (de) | Pharmazeutische Verwendung von 2,4,6,8-Tetramethyl-2,4,6,8-tetraazobicyclo-[3,3,0]-oktandion-3,7 | |
| DE2338901C2 (de) | Pharmazeutisches Präparat mit analgetischer Wirkung | |
| DE1518443C (de) | 2-(2,6-Dimethoxyphenoxyäthyl)-aminomethyl-l,4-benzodioxan und dessen Hydrochlorid sowie Verfahren zu deren Herstellung | |
| DE1966641C3 (de) | Verwendung von 4,4-Diarylpiperidinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |